abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English

Artikel

13 Mai 2004

Autor:
Lisa Richwine, Reuters

Pfizer to pay $430 million for false drug marketing

Pfizer has agreed to pay $430 million (245 million pounds) and plead guilty to criminal charges for illegally marketing an epilepsy drug for unapproved uses such as migraines and pain, U.S. prosecutors say...The company's Warner-Lambert division promoted the drug, Neurontin, for uses it had no scientific evidence to support...[also refers to TAP Pharmaceuticals (joint venture Abbott Laboratories & Takeda Chemical Industries)]